Biodesix Announces Second Quarter 2022 Results and Highlights
Second quarter 2022 core Lung Diagnostic revenue of $7.3 million increased 52% over the comparable period in 2021; Received Medicare coverage for the Nodify CDT® Lung Nodule Test; Announced strategic arrangements during the quarter (Royal Philips, Memorial Sloan Kettering Cancer Center and Bio-Rad); Reaffirm 2022 revenue outlook of between $37.5 million and $39.5 million; Conference … [Read more…]